Posterior reversible encephalopathy syndrome after intrathecal methotrexate infusion: a case report and literature update

Quantitative Imaging in Medicine and Surgery

Efterpi Pavlidou³  Athanasia Anastasiou¹  Emmanuel Hatzipantelis³  Zoi Pana³  Maria Kinali²  Vasiliki Tsotoulidou³  Evangelos Pavlou³ 

[1] Radiology Department, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece;;Paediatric Neurology Department, Chelsea and Westminster Hospital NHS, London, UKThe second Paediatric Department, Aristotle University of Thessaloniki, AHEPA University General Hospital, Thessaloniki, Greece;

关键词: Posterior reversible encephalopathy;    methotrexate (MTX);    children;    leukaemia;    lymphoma;   

DOI  :  10.21037/qims.2016.10.07

学科分类：外科医学

来源: AME Publications

【 摘 要 】

Posterior reversible encephalopathy syndrome (PRES) is a rare clinical-radiological entity characterised by seizures, severe headache, mental status instability and visual disturbances. Hypertension is typically present. We report a case of a 13-year old boy with Burkitt lymphoma/leukaemia, who presented with posterior leukoencephalopathy 24 hours after intrathecal methotrexate (MTX) infusion. The child presented with headache, seizures, elevated blood pressure and gradual deterioration of his neurological status. Midazolam, dexamethazone and furosemide were initiated leading to reduction of cerebral oedema and clinical improvement. A thorough literature review is discussed in this report. Pathophysiology of leukoencephalopathy remains unclear. It develops within 5�?14 days after intrathecal MTX and resolves within a week usually without permanent neurological sequelae. Broad use of MRI has led to an increasing number of identified cases of PRES. Treatment approach is mainly to manage the underlying cause of PRES. Prognosis is generally benign; however delayed diagnosis and improper management may result in permanent brain insult.

【 授权许可】

Unknown